News of Note—Sun Pharma slapped with Form 483; Catalent invests $14M; FDA draft guidance

iPhone
(Pixabay)

> Sun Pharmaceutical has been issued a Form 483 with 11 observations for its plant in Dadra, India. Story

> Somerset, New Jersey-based Catalent is investing $14 million to expand softgel capabilities at its facility in Eberbach, Germany, in response to demand for animal-free consumer health products. Release

> The FDA has issued new draft guidance for how companies should handle voluntary recalls. Release

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> East Rutherford, New Jersey-based CDMO Cambrex has opened a new 120-square-meter quality control laboratory at its site in Milan, Italy. Release

 

Suggested Articles

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.

Just amid a global retreat of Lartruvo, Eli Lilly's cancer portfolio suffers another setback as Verzenio runs into safety problems in Japan.

Catalent's newly acquired Paragon Bioservices will expand its capacity to as much as 425,000 square feet to manufacture therapies for Sarepta.